{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T18:13:32.064950+00:00","company":{"ticker":"GDRX","cik":1809519,"company_name":"GoodRx Holdings, Inc."},"pagination":{"limit":100,"returned":20,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"4c7b09023dcbce24b1aff7e31414aea6c532e8e0","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$1.2 million","period_text":"first quarter of 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$194.0 million"},"claim":"GoodRx Holdings, Inc. reported first quarter of 2026 results: revenue $194.0 million, net income $1.2 million. Guidance raised.","evidence_excerpt":"the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026 . First Quarter 2026 Highlights • Revenue of $194.0 million • Net income of $1.2 million ; Net income margin of 0.6% • Adjusted Net Income 1 of $23.0 million ; Adjusted Net Income Margin 1 of 11.9% • Adjusted EBITDA 1 of $58.3 million ;","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-26-000110","anchor_url":"https://secwatch.observer/filing/0001809519-26-000110#claim-4c7b09023dcbce24b1aff7e31414aea6c532e8e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000110/0001809519-26-000110-index.htm"},{"fact_type":"auditor_change","fact_key":"b724d41182a0f5f3c01103db9f39cba677ea88a4","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2026-03-18T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"PricewaterhouseCoopers LLP","disagreement_text":null,"effective_date":"2026-03-14","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"KPMG LLP"},"claim":"GoodRx Holdings, Inc. dismissed PricewaterhouseCoopers LLP as its auditor.","evidence_excerpt":"approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001809519-26-000059","anchor_url":"https://secwatch.observer/filing/0001809519-26-000059#claim-b724d41182a0f5f3c01103db9f39cba677ea88a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000059/0001809519-26-000059-index.htm"},{"fact_type":"auditor_change","fact_key":"1563d70929f984d898591f231540e65ccaba1914","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2026-03-18T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"KPMG LLP","disagreement_text":null,"effective_date":"2026-03-14","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"GoodRx Holdings, Inc. engaged KPMG LLP as its auditor.","evidence_excerpt":"the Audit and Risk Committee of the Board of Directors of GoodRx Holdings, Inc. (the “Company”), following a competitive proposal process, approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001809519-26-000059","anchor_url":"https://secwatch.observer/filing/0001809519-26-000059#claim-1563d70929f984d898591f231540e65ccaba1914","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000059/0001809519-26-000059-index.htm"},{"fact_type":"executive_change","fact_key":"fd8da5d5f9","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-02-05T23:59:59+00:00","payload":{"action":null,"action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-04","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Romin Nabiey changed role as Chief Accounting Officer at GoodRx Holdings, Inc..","evidence_excerpt":"Mr. McGinnis succeeds Romin Nabiey who, as previously disclosed, has been serving as Interim Chief Financial Officer.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001809519-25-000021","anchor_url":"https://secwatch.observer/filing/0001809519-25-000021#claim-fd8da5d5f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000021/0001809519-25-000021-index.htm"},{"fact_type":"executive_change","fact_key":"ab07329d41","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-02-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-04","interim":false,"role":"Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Christopher A. McGinnis was appointed as Chief Financial Officer and Treasurer at GoodRx Holdings, Inc..","evidence_excerpt":"On February 4, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Christopher A. McGinnis as Chief Financial Officer and Treasurer of the Company, effective as of his commencement of employment, which occurred on February 4, 2025 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-25-000021","anchor_url":"https://secwatch.observer/filing/0001809519-25-000021#claim-ab07329d41","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000021/0001809519-25-000021-index.htm"},{"fact_type":"executive_change","fact_key":"db95ebe2b2","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-01-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-01-21","interim":false,"role":"Director","role_category":"director","successor_name":"Scott Wagner","successor_named":true},"claim":"Simon Patterson resigned as Director at GoodRx Holdings, Inc..","evidence_excerpt":"On January 21, 2025, Simon Patterson resigned as a member of the Board and as a member of the Board’s Nominating and Corporate Governance Committee and Innovation Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-25-000015","anchor_url":"https://secwatch.observer/filing/0001809519-25-000015#claim-db95ebe2b2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000015/0001809519-25-000015-index.htm"},{"fact_type":"executive_change","fact_key":"ecd79f7327","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-01-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-21","interim":false,"role":"Co-Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Scott Wagner was appointed as Co-Chair of the Board at GoodRx Holdings, Inc..","evidence_excerpt":"The Board also appointed Mr. Wagner as the Chair of the Board’s Compensation Committee, and appointed Mr. Wagner as a Co-Chair of the Board, to serve in such role together with the existing Chair (now to be referred to as Co-Chair), Trevor Bezdek.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-25-000015","anchor_url":"https://secwatch.observer/filing/0001809519-25-000015#claim-ecd79f7327","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000015/0001809519-25-000015-index.htm"},{"fact_type":"executive_change","fact_key":"13e068cbc0","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-01-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-21","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Scott Wagner was appointed as Class II Director at GoodRx Holdings, Inc..","evidence_excerpt":"On January 21, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-25-000015","anchor_url":"https://secwatch.observer/filing/0001809519-25-000015#claim-13e068cbc0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000015/0001809519-25-000015-index.htm"},{"fact_type":"executive_change","fact_key":"3849605203","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-01-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-17","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Romin Nabiey was appointed as Interim Chief Financial Officer at GoodRx Holdings, Inc..","evidence_excerpt":"On January 10, 2025, the Board of Directors (the “Board”) of the Company appointed Romin Nabiey, the Company’s current Chief Accounting Officer, as Interim Chief Financial Officer of the Company, effective as of the Effective Date.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-25-005050","anchor_url":"https://secwatch.observer/filing/0001193125-25-005050#claim-3849605203","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000119312525005050/0001193125-25-005050-index.htm"},{"fact_type":"executive_change","fact_key":"a2a6695b4a","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-01-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-01-17","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Romin Nabiey","successor_named":true},"claim":"Karsten Voermann resigned as Chief Financial Officer at GoodRx Holdings, Inc..","evidence_excerpt":"On January 7, 2025, Karsten Voermann submitted his resignation as Chief Financial Officer of GoodRx Holdings, Inc. (the “Company”), effective January 17, 2025 (the “Effective Date”) for personal reasons.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-25-005050","anchor_url":"https://secwatch.observer/filing/0001193125-25-005050#claim-a2a6695b4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000119312525005050/0001193125-25-005050-index.htm"},{"fact_type":"executive_change","fact_key":"8afb797439","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-10-28T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ronald E. Bruehlman was elected as Director at GoodRx Holdings, Inc..","evidence_excerpt":"On October 25, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ronald E. Bruehlman as a Class III director, effective as of the Effective Date, to fill the vacancy on the Board created by the resignation of Julie Bradley.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000188","anchor_url":"https://secwatch.observer/filing/0001809519-24-000188#claim-8afb797439","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000188/0001809519-24-000188-index.htm"},{"fact_type":"executive_change","fact_key":"e974fb5727","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-10-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-08","interim":false,"role":"Director","role_category":"director","successor_name":"Ronald E. Bruehlman","successor_named":true},"claim":"Julie Bradley resigned as Director at GoodRx Holdings, Inc..","evidence_excerpt":"On October 22, 2024, Julie Bradley notified GoodRx Holdings, Inc. (the “Company”) of her decision to resign as a member of the Board of Directors of the Company (the “Board”), including from her service on the Board’s Audit and Risk Committee, effective as of November 8, 2024 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000188","anchor_url":"https://secwatch.observer/filing/0001809519-24-000188#claim-e974fb5727","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000188/0001809519-24-000188-index.htm"},{"fact_type":"executive_change","fact_key":"be2f4b1bc6","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-07-10T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-08","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ian T. Clark was elected as Class III Director at GoodRx Holdings, Inc..","evidence_excerpt":"On July 8, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ian T. Clark as a Class III director, effective immediately, to fill the vacancy on the Board created by the resignation of Stephen LeSieur.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000133","anchor_url":"https://secwatch.observer/filing/0001809519-24-000133#claim-be2f4b1bc6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000133/0001809519-24-000133-index.htm"},{"fact_type":"executive_change","fact_key":"c0f3fdd107","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-05-30T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-29","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Simon Patterson was elected as Class II Director at GoodRx Holdings, Inc..","evidence_excerpt":"On May 29, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Simon Patterson as a Class II director, effective immediately, to fill the vacancy on the Board created by the resignation of Adam Karol.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000094","anchor_url":"https://secwatch.observer/filing/0001809519-24-000094#claim-c0f3fdd107","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000094/0001809519-24-000094-index.htm"},{"fact_type":"earnings_release","fact_key":"cbd3aa19c2b0d8ee3d7f50a9fda91a13fd494d75","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $1.0 million","period_text":"the three months ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$197.9 million"},"claim":"GoodRx Holdings, Inc. reported the three months ended March 31, 2024 results: revenue $197.9 million, net income Net loss of $1.0 million.","evidence_excerpt":"for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights • Revenue 1 and Adjusted Revenue 1 of $197.9 million • Net loss of $1.0 million; Net loss margin of 0.5% • Adjusted Net Income 1 of $32.6 million; Adjusted Net Income Margin 1 of 16.5% • Adjusted EBITDA 1 of $62.8 million; Adjusted","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000081","anchor_url":"https://secwatch.observer/filing/0001809519-24-000081#claim-cbd3aa19c2b0d8ee3d7f50a9fda91a13fd494d75","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000081/0001809519-24-000081-index.htm"},{"fact_type":"executive_change","fact_key":"cc55b00568","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Stephen LeSieur resigned as Director at GoodRx Holdings, Inc..","evidence_excerpt":"Also on March 12, 2024, Stephen LeSieur notified the Company of his decision to resign as a member of the Board, effective as of March 14, 2024, including from his service on the Board’s Compliance Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000048","anchor_url":"https://secwatch.observer/filing/0001809519-24-000048#claim-cc55b00568","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000048/0001809519-24-000048-index.htm"},{"fact_type":"executive_change","fact_key":"574b654571","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-22","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Adam Karol resigned as Director at GoodRx Holdings, Inc..","evidence_excerpt":"On March 12, 2024, Adam Karol notified the Company of his decision to resign as a member of the Board, effective as of March 22, 2024, including from his service on the Board’s Compliance Committee and Nominating and Corporate Governance Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000048","anchor_url":"https://secwatch.observer/filing/0001809519-24-000048#claim-574b654571","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000048/0001809519-24-000048-index.htm"},{"fact_type":"earnings_release","fact_key":"d7096ccdf3485c3f0303b182112a235829d5a269","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-02-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months and year ended December 31, 2023","report_date":"2024-02-29","result_type":"reported_results","revenue_text":null},"claim":"GoodRx Holdings, Inc. reported financial results for the three months and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, GoodRx Holdings, Inc. (the “Company”) announced the Company’s financial results for the three months and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this report.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000029","anchor_url":"https://secwatch.observer/filing/0001809519-24-000029#claim-d7096ccdf3485c3f0303b182112a235829d5a269","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000029/0001809519-24-000029-index.htm"},{"fact_type":"material_agreement","fact_key":"bcb4cb2d2985278eab33fa2176c30b71189bee78","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Fifth Amendment to First Lien Credit Agreement","agreement_type":"credit_facility","counterparty":"Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto","effective_date":"2024-02-20","item_codes_triggered":["1.01"],"value_text":null},"claim":"GoodRx Holdings, Inc. entered into Fifth Amendment to First Lien Credit Agreement with Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto (effective 2024-02-20).","evidence_excerpt":"On February 20, 2024, GoodRx, Inc. (“GoodRx”), an indirect wholly-owned subsidiary of GoodRx Holdings, Inc. (the “Company”), entered into the Fifth Amendment to First Lien Credit Agreement (the “Fifth Amendment”), by and among GoodRx, as borrower, GoodRx Intermediate Holdings, LLC and the other guarantors party thereto (collectively, together with GoodRx, the “Loan Parties”), Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto, in order to amend its First Lien Credit Agreement, dated as of October 12, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), to, among other things, extend the maturity date of its $100.0 million revolving credit facility thereunder from October 11, 2024 to July 11, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001809519-24-000020","anchor_url":"https://secwatch.observer/filing/0001809519-24-000020#claim-bcb4cb2d2985278eab33fa2176c30b71189bee78","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000020/0001809519-24-000020-index.htm"},{"fact_type":"executive_change","fact_key":"08bca086e6","cik":1809519,"ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"action":"removed","action_category":"departure","departure_tone":"abrupt","effective_date":"2024-02-15","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Raj Beri was removed as Chief Operating Officer at GoodRx Holdings, Inc..","evidence_excerpt":"As previously disclosed, on January 16, 2024, the Company determined that the role currently held by Raj Beri, the Company's Chief Operating Officer, would be eliminated and the Company’s Board of Directors removed Mr. Beri as Chief Operating Officer, effective as of February 15, 2024 (the “Separation Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001809519-24-000020","anchor_url":"https://secwatch.observer/filing/0001809519-24-000020#claim-08bca086e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000020/0001809519-24-000020-index.htm"}]}